@article{fdi:010061803,
  title = {{A}bsence of an association between {P}lasmodium falciparum infection and post-ivermectin {L}oa-related non-neurologic serious adverse events},
  author = {{F}okom-{D}omgue, {J}. and {P}ion, {S}{\'e}bastien and {G}ounoue, {R}. and {A}kame, {J}. and {N}guipdop-{D}jomo, {P}. and {T}wum-{D}anso, {N}. {A}. {Y}. and {T}hylefors, {B}. and {B}oussinesq, {M}ichel and {K}amgno, {J}.},
  editor = {},
  language = {{ENG}},
  abstract = {{A}lthough ivermectin treatment can induce serious adverse events ({SAE}s) in individuals harboring high {L}oa loa microfilaremia (mf), not all patients with high mf levels develop such reactions, suggesting that cofactors may be involved. {A} study was conducted in {C}ameroon to investigate the possible role of {P}lasmodium coinfection at the time of ivermectin treatment in the development of {SAE}s. {B}efore their first ivermectin treatment, thick smears were obtained from 4,175 individuals to determine the burden of {P}lasmodium sp., {L}. loa, and {M}ansonella perstans. {A}fter treatment, 18 (4.3 per 1,000) patients developed a non-neurologic {SAE}. {L}ogistic regression analysis, adjusting for age, sex, {P}. falciparum infection, and {M}. perstans infection intensities, confirmed that {L}. loa mf was the main risk factor for {SAE}s. {W}e found no evidence that coinfection with {P}. falciparum at the time of ivermectin treatment was associated with the occurrence of {L}oa-related {SAE}s in this population.},
  keywords = {{CAMEROUN}},
  booktitle = {},
  journal = {{A}merican {J}ournal of {T}ropical {M}edicine and {H}ygiene},
  volume = {90},
  numero = {2},
  pages = {335--338},
  ISSN = {0002-9637},
  year = {2014},
  DOI = {10.4269/ajtmh.13-0189},
  URL = {https://www.documentation.ird.fr/hor/fdi:010061803},
}